Abstract
Background
Janssen Research & Development, LLC, part of the Janssen pharmaceutical companies of Johnson & Johnson, and NYU School of Medicine partnered to establish the Compassionate Use Advisory Committee (CompAC) to evaluate the use of an independent, external, expert committee in ensuring transparent, fair, beneficent, evidence-based, and patient-focused compassionate access to investigational medicines, a public health challenge that has been an ongoing issue for over 3 decades.
Methods
To this end, NYU School of Medicine was responsible for the formation, member selection, and operation of CompAC, consisting of physicians, ethicists, and patient advocates, under Johnson & Johnson’s sponsorship.
Results
A pilot was successfully run using CompAC to provide recommendations on compassionate use access to a Johnson & Johnson oncology investigational asset called daratumumab.
Conclusion
This innovative model provides a framework that can be emulated by the industry globally.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenblatt M, Kuhlik B. Principles and challenges in access to experimental medicines. JAMA. 2015;313:2023–2024.
Caplan AL, Ray A. The ethical challenges of compassionate use. JAMA. 2016;315:979–980.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caplan, A., Bateman-House, A., Waldstreicher, J. et al. A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC). Ther Innov Regul Sci 53, 243–248 (2019). https://doi.org/10.1177/2168479018759659
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018759659